香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 截至本公告日期，董事會成員包括執行董事李松博士、Wentao Zhang博士及 Zhongping Lin博士；非執行董事Yin Zhuan女士及吳灝先生；及獨立非執行董事 李軼梵先生、劉二飛先生及王勁松博士。 * 僅供識別 茲提述方達控股公司（「本公司」）日期為2025年10月10日有關訂立股份轉讓協議 的公告（「該公告」）。除文義另有所指外，本公告所用詞彙與該公告所界定者具有 相同涵義。 如該公告所述，一份載有（其中包括）(i)有關股份轉讓協議及其項下擬進行交易的 進一步資料；(ii)獨立董事委員會向獨立股東提出的建議；(iii)獨立財務顧問致獨 立董事委員會及獨立股東的函件；(iv)目標集團的財務資料；(v)經擴大集團之未 經審核備考財務資料；(vi)估值報告；及( ...

公司名稱: 方達控股公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01521 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | ...

Core Viewpoint - Fangda Holdings (01521) reported a revenue of approximately $191.4 million for the nine months ending September 30, 2025, representing a 0.2% increase compared to the same period in 2024 [1] Financial Performance - The net profit for the nine months ending September 30, 2025, was approximately $5.6 million, a significant increase from $200,000 in the same period of 2024 [1] - Adjusted net profit, excluding share-based compensation expenses, amortization of acquired intangible assets, and acquisition-related expenses, was approximately $12.6 million, reflecting a 32.5% increase compared to the same period in 2024 [1] Asset Position - As of September 30, 2025, the unaudited consolidated net asset value of the group was approximately $345 million [1]

Core Insights - The company reported a revenue of approximately $191.4 million for the nine months ending September 30, 2025, representing a 0.2% increase compared to the same period in 2024 [1] - The net profit for the same period was approximately $5.6 million, a significant increase from $200,000 in the previous year [1] - Adjusted net profit, excluding share-based compensation, amortization of acquired intangible assets, and acquisition-related expenses, was approximately $12.6 million, reflecting a 32.5% increase year-over-year [1] - As of September 30, 2025, the company's unaudited consolidated net asset value was approximately $345 million [1]

于2025年9月30日，集团的未经审核综合资产净值约为345.0百万美元。 格隆汇10月28日丨方达控股(01521.HK)公布，集团截至2025年9月30日止九个月的收益约为191.4百万美 元，较2024年同期增加0.2%。集团于截至2025年9月30日止九个月的纯利约为5.6百万美元，较截至2024 年9月30日止九个月的纯利约0.2百万美元大幅增长。经扣除以股份为基础的薪酬开支、并购所得无形资 产摊销及并购相关开支后，集团截至2025年9月30日止九个月的经调整纯利约为12.6百万美元，较2024 年同期增加32.5%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） 本集團截至2025年9月30日止九個月的收益約為191.4百萬美元，較2024年同期增 加0.2%。本集團於截至2025年9月30日止九個月的純利約為5.6百萬美元，較截至 2024年9月30日止九個月的純利約0.2百萬美元大幅增長。經扣除以股份為基礎的 薪酬開支、併購所得無形資產攤銷及併購相關開支後，本集團截至2025年9月30 日止九個月的經調整純利約為12.6百萬美元，較2024年同期增加32.5%。 於2025年9月30日，本集團的未經審核綜合資產淨值約為345.0百萬美元。 1 本公司股東及潛在投資者務請注意，本公告所載資料乃未經審核，亦未經本公司 核數師或本公司董事會審核委員會審閱。本公司股東及潛在投資者於買賣本公司 股份時務請審慎行事。 承董事會命 方達控股公司* 主席 李松博士 香 ...

Group 1 - The acquisition involves a total consideration of RMB 270 million, with the target company becoming a wholly-owned subsidiary of the acquiring company after the transaction [1] - The target company specializes in clinical trial technology services and related laboratory services, enhancing the acquiring company's global laboratory service capabilities and influence in China [2] - The acquisition is expected to strengthen the acquiring company's position as a trusted partner in the clinical research industry by expanding its center laboratory services in China and the Asia-Pacific region [2] Group 2 - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas and is known for its compliance with Good Clinical Practice (GCP) [2] - The acquisition will enhance the ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits [2]

Core Viewpoint - The acquisition of 100% equity in Shanghai Guanhua Medical Technology Co., Ltd. by Fangda Holdings aims to enhance the group's global laboratory service capabilities and strengthen its influence in China [1][2] Group 1: Acquisition Details - Fangda Holdings' wholly-owned subsidiary, Fangda Shanghai, plans to acquire Shanghai Guanhua Medical Technology for a total consideration of RMB 270 million [1] - The target company specializes in clinical trial technology services, related services, and laboratory services [1] Group 2: Strategic Objectives - The acquisition is intended to expand the group's central laboratory services in China and enhance its influence in the Asia-Pacific region [1] - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas, known for its compliance with Good Clinical Practice (GCP) and internationally recognized services [1][2] Group 3: Synergy and Market Position - The target group's strong track record, including its role in the successful launch of 35 new drugs and support for regulatory audits, complements the existing expertise of the group [2] - The acquisition will enhance the group's ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions, further solidifying its position as a trusted partner in the clinical research industry [2]

Group 1 - The company Fonda Holdings (01521) has entered into a share transfer agreement to acquire Shanghai Guanhua Medical Technology Co., Ltd. for a total consideration of RMB 270 million, which will make the target company a wholly-owned subsidiary after completion [1][2] - The acquisition aims to enhance the group's global laboratory service capabilities and strengthen its influence in China, as the target group is a leading provider of clinical research laboratory services with extensive experience in supporting over 1,500 clinical trials [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits, which aligns well with the group's existing expertise [2] Group 2 - The target company primarily engages in clinical trial technology services, related services, and laboratory services, with its wholly-owned subsidiaries focusing on clinical research services [2] - Following the acquisition, the group's financial performance will be consolidated into its financial statements, and the registered capital of the target company will be reduced to RMB 45,169,326 after the buyback and capital reduction [1] - The acquisition is expected to be completed by October 31, 2025, and will further solidify the group's position as a trusted partner in the clinical research industry by enhancing its ability to provide high-quality one-stop services to pharmaceutical companies and research institutions [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 有關收購目標公司全部已發行股本的 重大及關連交易 上市規則之涵義 由於收購事項之最高適用百分比率（定義見上市規則）高於25%但低於100%，故 收購事項構成本公司之主要交易，因此須遵守上市規則第十四章項下的申報、 公告、通函及股東批准規定。 1 截至本公告日期，杭州泰格為本公司的控股股東，通過香港泰格直接及間接持 有合共佔已發行股份總數約64.57%。因此，杭州泰格及嘉興欣格均為本公司之 關連人士，而根據上市規則第十四A章，收購事項構成本公司之關連交易。鑒於 收購事項之最高適用百分比率（定義見上市規則）超過5%，收購事項須遵守上市 規則第十四A章項下的申報、公告、通函及獨立股東批准規定。 獨立董事委員會及獨立財務顧問 本公司已成立由全體獨立非執行董事組成的獨立董事委員會， ...